Forest’s Recent Launches Boosting Diversity, But Gaining Traction Slowly
This article was originally published in The Pink Sheet Daily
Executive Summary
One exception to the slow-growth outlook is the surprise success of Bystolic (nebivolol), the 16th beta blocker to enter the heavily generalized market, but a product the firm has been able to differentiate more by its tolerability than its efficacy.